Globus Medical (NYSE:GMED) Analyst Rating Consensus

Globus Medical (NYSE:GMED) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.55 by 10 Brokerage Firm. 7 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating. 1 Brokerage Firms have advised hold. A sell rating was given by 1 analyst.

Other Equity analysts have also commented on the company shares. Barclays initiates coverage on Globus Medical (NYSE:GMED). In the latest research report, Barclays announces the target price to $26 per share. According to the latest information available, the shares are now rated Equal-weight by the analysts at the agency. The rating by the firm was issued on May 27, 2016.

Globus Medical (NYSE:GMED): 7 Analyst have given the stock of Globus Medical (NYSE:GMED) a near short term price target of $28.86. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $2.12. The higher price target estimate is at $33 while the lower price estimates are fixed at $26.

Globus Medical (NYSE:GMED) witnessed a decline in the market cap on Tuesday as its shares dropped 2.89% or 0.69 points. After the session commenced at $23.89, the stock reached the higher end at $23.89 while it hit a low of $22.98. With the volume soaring to 1,347,661 shares, the last trade was called at $23.18. The company has a 52-week high of $28.99. The company has a market cap of $2,214 million and there are 95,510,383 shares in outstanding. The 52-week low of the share price is $20.48.

Globus Medical, Inc. has lost 3.82% in the last five trading days and dropped 1.15% in the last 4 weeks. Globus Medical, Inc. is up 1.27% in the last 3-month period. Year-to-Date the stock performance stands at -16.68%.

Globus Medical, Inc. is a medical device company. The Company is focused on developing products for patients with musculoskeletal disorders and spine disorders. Its products consist of two categories: Innovative Fusion and Disruptive Technologies. Innovative Fusion products comprise fusion products to treat various spinal disorders for the entire spine and can be used in various surgical approaches. Disruptive Technologies represents a shift in the treatment of spinal disorders by allowing for surgical procedures and the treatment of spinal disorders. The Companys portfolio of Disruptive Technology products includes products that allow for minimally invasive surgical (MIS) techniques, as well as treatment alternatives, including motion preservation technologies, such as dynamic stabilization, total disc replacement and interspinous process spacer products, and biomaterials technologies, as well as interventional pain management solutions.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.